| Assessment Status | Rapid Review Complete |
| HTA ID | 23059 |
| Drug | Atogepant |
| Brand | Aquipta® |
| Indication | Atogepant is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month. |
| Assessment Process | |
| Rapid review commissioned | 20/09/2023 |
| Rapid review completed | 26/10/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atogepant on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations. February 2025
